Nanowear, the connected-care and remote diagnosis network focused on nanotechnology, teamed up with Hackensack Meridian Health Services, New Jersey ‘s largest healthcare system, and Brooklyn, NY’s Maimonides Medical Centre to come up with precision medicine clinical-grade, cloth based wearable technology for COVID-19 remote diagnosis.

The goal is to evaluate patients with reported or suspected COVID-19 with Nanowear ‘s proprietary and patented fabric-based nanosensors that detect changes in physiology and biomarker suggesting clinical deterioration that may need further intervention from hospital systems.

Nanowear’s innovative technology makes a groundbreaking leap forward in remote medical diagnostics and telemedicine. If a patient wears SimpleSENSE, the customizable-size undergarment of Nanowear, doctors can catch and test several physiological signals remotely including real-time ECG, systolic and diastolic blood pressure, hemodynamic blood supply, respiration, lung and fluid volume, and temperature levels All without an in-person consultation or a direct contact.

Nanowear ‘s garment collects 120 million pieces of data per patient every day through data from coronary, renal, and circulatory biomarkers that are communicated to healthcare personnel so that they can make better and faster remote decisions.

The COVID-19 disease outbreak has changed the provision and treatment of health care; a physician’s conventional view of personally inspecting or treating a patient in person has been disrupted, possibly permanently, and will have a profound effect on the future of patient-physicist clinical experiences expansively from primary care to cases of chronic disease.

Nanowear’s textile-embedded multi-parameter nanosensors are clinical-grade, measuring several cardiac, pulmonary, and circulatory biomarkers, and generating a standardized, customizable digital signature for each patient, unlike wearable clothing, smartwatches, iphones, or limited-metric adhesive patches.

(Nanowear has applied Class II 510(k)’s approval of its SimpleSENSE app and smartphone application to FDA. SimpleSENSE is not yet approved by the FDA and is not currently intended to alleviate, avoid, treat, heal or diagnose any disease or disorder.)